| Literature DB >> 22521560 |
Mallika Tewari1, Shipra Sahai, Raghvendra R Mishra, Sunit K Shukla, Hari S Shukla.
Abstract
Advanced gastric cancer carries a very poor prognosis when the tumor becomes unresectable. Even with the best currently available chemotherapy regimens the survival rate remains dismal. A recent breakthrough in the treatment paradigm has been the approval of trastuzumab, a monoclonal antibody, in HER2-positive metastatic gastric cancer. A large number of trials are underway using dendritic cells (DCs) in a number of human malignancies and do show a ray of hope in management of these patients. This review attempts to summarize tumor immunology and the current data regarding use of DCs in gastric cancer therapy.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22521560 DOI： 10.1016/j.suronc.2012.03.003
Source DB: PubMed Journal: Surg Oncol ISSN： 0960-7404 Impact factor: 3.279